This company has been marked as potentially delisted and may not be actively trading. BioTelemetry (BEAT) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesShort InterestTrendsBuy This Stock BEAT vs. DRTS, SKIN, CATX, BWAY, OSUR, SGHT, UTMD, RCEL, ANIK, and TLSIShould you be buying BioTelemetry stock or one of its competitors? The main competitors of BioTelemetry include Alpha Tau Medical (DRTS), Beauty Health (SKIN), Perspective Therapeutics (CATX), BrainsWay (BWAY), OraSure Technologies (OSUR), Sight Sciences (SGHT), Utah Medical Products (UTMD), AVITA Medical (RCEL), Anika Therapeutics (ANIK), and TriSalus Life Sciences (TLSI). These companies are all part of the "surgical & medical instruments" industry. BioTelemetry vs. Alpha Tau Medical Beauty Health Perspective Therapeutics BrainsWay OraSure Technologies Sight Sciences Utah Medical Products AVITA Medical Anika Therapeutics TriSalus Life Sciences BioTelemetry (NASDAQ:BEAT) and Alpha Tau Medical (NASDAQ:DRTS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk, institutional ownership and community ranking. Does the media prefer BEAT or DRTS? In the previous week, Alpha Tau Medical had 6 more articles in the media than BioTelemetry. MarketBeat recorded 6 mentions for Alpha Tau Medical and 0 mentions for BioTelemetry. Alpha Tau Medical's average media sentiment score of 0.39 beat BioTelemetry's score of 0.00 indicating that Alpha Tau Medical is being referred to more favorably in the news media. Company Overall Sentiment BioTelemetry Neutral Alpha Tau Medical Neutral Is BEAT or DRTS more profitable? Alpha Tau Medical's return on equity of -38.62% beat BioTelemetry's return on equity.Company Net Margins Return on Equity Return on Assets BioTelemetryN/A -175.50% -154.96% Alpha Tau Medical N/A -38.62%-29.89% Do analysts recommend BEAT or DRTS? BioTelemetry currently has a consensus price target of $8.00, suggesting a potential upside of 385.44%. Alpha Tau Medical has a consensus price target of $8.00, suggesting a potential upside of 166.67%. Given BioTelemetry's higher possible upside, research analysts plainly believe BioTelemetry is more favorable than Alpha Tau Medical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioTelemetry 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Alpha Tau Medical 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, BEAT or DRTS? BioTelemetry has a beta of -0.71, meaning that its share price is 171% less volatile than the S&P 500. Comparatively, Alpha Tau Medical has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Do institutionals and insiders believe in BEAT or DRTS? 7.8% of BioTelemetry shares are owned by institutional investors. Comparatively, 2.7% of Alpha Tau Medical shares are owned by institutional investors. 20.9% of BioTelemetry shares are owned by company insiders. Comparatively, 39.5% of Alpha Tau Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor BEAT or DRTS? BioTelemetry received 370 more outperform votes than Alpha Tau Medical when rated by MarketBeat users. However, 72.41% of users gave Alpha Tau Medical an outperform vote while only 63.27% of users gave BioTelemetry an outperform vote. CompanyUnderperformOutperformBioTelemetryOutperform Votes39163.27% Underperform Votes22736.73% Alpha Tau MedicalOutperform Votes2172.41% Underperform Votes827.59% Which has stronger valuation & earnings, BEAT or DRTS? Alpha Tau Medical is trading at a lower price-to-earnings ratio than BioTelemetry, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioTelemetryN/AN/A-$14.64M-$0.68-2.42Alpha Tau MedicalN/AN/A-$29.16M-$0.45-6.67 SummaryAlpha Tau Medical beats BioTelemetry on 9 of the 14 factors compared between the two stocks. Get BioTelemetry News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BEAT vs. The Competition Export to ExcelMetricBioTelemetrySurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.46M$4.38B$5.33B$8.31BDividend YieldN/A45.13%5.27%4.09%P/E Ratio-2.4229.0626.7119.58Price / SalesN/A73.00395.60135.07Price / CashN/A51.0838.3234.62Price / Book2.706.186.764.50Net Income-$14.64M$66.96M$3.23B$248.40M BioTelemetry Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BEATBioTelemetry1.9045 of 5 stars$1.65-21.1%$8.00+385.4%-39.0%$55.46MN/A-2.421,700Gap UpDRTSAlpha Tau Medical1.9637 of 5 stars$3.10+11.1%$8.00+158.1%+13.2%$218.18MN/A-7.2180Earnings ReportGap UpHigh Trading VolumeSKINBeauty Health0.3731 of 5 stars$1.64-5.7%$1.42-13.6%-37.4%$217.93M$322.47M-3.901,030Positive NewsGap DownCATXPerspective Therapeutics3.2251 of 5 stars$2.73+3.8%$12.50+357.9%-84.2%$202.64M$1.43M0.0070News CoverageAnalyst RevisionBWAYBrainsWay3.5858 of 5 stars$10.65+7.5%$14.25+33.8%+100.6%$200.99M$43.46M106.51120OSUROraSure Technologies4.0166 of 5 stars$2.63+8.2%$3.00+14.1%-48.8%$196.72M$161.63M17.53840Gap DownSGHTSight Sciences4.0247 of 5 stars$3.27-7.9%$3.92+19.8%-39.4%$183.52M$78.11M-3.21210Positive NewsAnalyst ForecastGap DownUTMDUtah Medical Products2.0294 of 5 stars$54.47-1.1%N/A-19.8%$178.77M$39.27M13.79180Dividend AnnouncementRCELAVITA Medical1.1875 of 5 stars$6.74+4.3%$17.25+155.9%-23.6%$178.17M$71.66M-2.82130Positive NewsANIKAnika Therapeutics4.1065 of 5 stars$12.16-0.2%$21.33+75.4%-54.5%$174.39M$117.05M-1.83300Positive NewsTLSITriSalus Life Sciences2.5358 of 5 stars$5.18+0.8%$10.93+111.0%-41.7%$167.17M$29.43M-2.08106News CoverageAnalyst Revision Related Companies and Tools Related Companies Alpha Tau Medical Alternatives Beauty Health Alternatives Perspective Therapeutics Alternatives BrainsWay Alternatives OraSure Technologies Alternatives Sight Sciences Alternatives Utah Medical Products Alternatives AVITA Medical Alternatives Anika Therapeutics Alternatives TriSalus Life Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BEAT) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioTelemetry, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioTelemetry With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BEAT Stock Free BEAT Stock Alerts